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Anticancer drugs, primarily taxanes are known to 
induce a very harrowing and sometimes long-running 
hair loss also known as taxane-induced alopecia. It is 
a transitory and usually reversible after effect of 
anticancer therapy that can have a devastating effect 
on psychological wellbeing of the patient.1 The severe 
emotional trauma due to hair loss may lead to refusal 
or delay in cancer treatment.2-3 The resolving time 
may last for several months to years. Long lasting 
nature of this condition may result in the 
amplification of the psychological impact of the 
disease and related treatment. It is also really not 
known that why some patients show greater hair loss 
as compared to others even with the same drug and 
the same dosage. 
 
Currently, scalp cooling is the only preventive 
treatment available for tackling chemotherapy 
associated alopecia, but clinical efficacy of the same 
is yet unsatisfactory and hard to speculate, especially 
in cases of taxane related hair loss.4 Marks DH et al., 
in a systematic review, concluded that scalp cooling 
systems and scalp hypothermia with cold caps are 
reported to show satisfactory effectiveness in the 
treatment of hair loss caused as an adverse reaction 
due to taxane chemotherapy.5 A treatment approach 
would only show good results if the mechanism of 
hair loss following chemotherapy is brought to light. 
Purba et al, in their sensational research, explored 
how taxanes (docetaxel and paclitaxel) damage 
human scalp hair follicles in a clinically appropriate 
ex-vivo organ culture model. As per their results, 
taxane use results in alopecia through several 
mechanisms including induction of the massive 
stockpiling of phospho-histone H3+ cells in the 
anagen matrix of human scalp hair follicles and 
agglomeration of cleaved caspase-3+ and pH3+ cells 
within the stem/progenitor-rich outer root sheath.  
 
They also stimulate micronucleation, transcriptional 
arrest and cell death in keratinocytes of hair matrix. 
Additionally, taxanes induce cell death and mitotic 
defects  within  human  hair  follicle  K15+  epithelial  
 
 
 
stem and progenitor cell niches.6 
 
In their research, Purba et al. revealed how taxanes 
damage stem, progenitor and transit amplifying cell 
niches in the human hair follicles in a cell cycle-
dependent fashion and uncovered an interestingly 
new  management tactic for chemotherapy associated 
alopecia, that is hair follicle protection through 
targeted cell cycle arrest. They also reported that 
palbociclib, the G1 arresting CDK4/6 inhibitor 
antagonises the mitosis-targeting cell toxicity of 
taxane chemotherapy in stem cell and transit 
amplifying cell compartments in the human hair 
follicle, without promoting premature catagen or 
causing adverse events related to hair follicles.6 
 
Their recently developed and clinically relevant 
human model of taxane associated hair follicle 
damage provides an invaluable preclinical research 
tool for developing novel strategies to manage 
taxane-induced hair loss and protect against human 
epithelial stem cell toxicity. Moreover, they have 
provided a proof-of-principle of a novel therapeutic 
approach, i.e. pharmacological G1 arrest, that could 
mitigate taxane-induced hair follicle damage and 
prevent subsequent chemotherapy-induced alopecia 
through the topical delivery of G1 arresting agents.6 
This breakthrough discovery will further help in 
unlocking more mechanisms that result in taxane 
induced hair loss leading to development of more safe 
and efficacious treatment modalities. 
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